Table 2.

Correlation of clinicopathologic characteristics of patients with pancreatic ductal adenocarcinoma who underwent pancreatectomy and CDO1 methylation

Variable		>19	<19	P valuea	Variable		>19>	<19	P valuea
UICC stage	0	0	1	.0070	v	Negative	4	11	.060
	I	1	7			Positive	75	70
	II	57	64		ne	Negative	4	12	.036
	III	7	0			Positive	75	69
	IV	14	9		CH	Negative	41	36	.300
T	1	1	4	.0018		Positive	38	45
	2	2	7		DU	Negative	45	45	.500
	3	39	53			Positive	34	36
	4	37	16		RP	Negative	21	40	.003
N	Negative	14	30	.0060		Positive	58	41
	Positive	65	51		PV	Negative	58	72	.010
Infiltration	INFa	1	0	.2000		Positive	21	9
	INFb	49	59		A	Negative	56	70	.016
	INFg	29	22			Positive	23	11
Location	Ph	54	60	.4000	PL	Negative	56	70	.016
	Pb	25	21			Positive	23	11
Histology	mod	32	30	.9000	CA19‐9	<37	19	20	.900
	pap	3	3			Over 37	60	61
	por	13	11		DPM	Negative	43	57	.037
	well	31	36			Positive	36	24
ly	Negative	8	15	.1000
	Positive	71	66

Bold values indicate significance.

^aχ² test.

A, arterial system invasion; CA, carbohydrate antigen; CH, distal bile duct invasion; DPM, dissected pancreatic tissue margin; DU, duodenal invasion; ly, lymphatic invasion; mod, moderate; ne, intrapancreatic nerve invasion; pap, papillary; Pb, body of pancreas; Ph, head of pancreas; PL, extrapancreatic nerve plexus invasion; por, poor; PV, portal venous system invasion; RP, retropancreatic tissue invasion; v, venous invasion.